May 6th 2024
Investigators analyzed data from the Center for International Blood and Marrow Transplant Research who underwent autologous or allogeneic transplants.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Stringent Complete Response in Multiple Myeloma Associated With Best Survival Outcomes
November 29th 2013Patients able to achieve stringent complete response after undergoing autologous stem-cell transplantation for multiple myeloma achieved improved long-term outcomes, including overall survival and time to progression, compared with patients who achieved lesser levels of response.
Shining a Warm Light on Cryoglobulinemia
November 15th 2013We recommend screening for cryoglobulinemia in all patients with HCV infection, livedo reticularis, vasculitic cutaneous ulcers, positive rheumatoid factor or rheumatoid vasculitis, membranoproliferative glomerulonephritis, or atypical Waldenström macroglobulinemia.
In spite of the complicated etiologic, clinical, and pathologic scenario of cryoglobulinemia, physicians can play a key role in its successful management by early recognition of the most common clinical presentations.
Gemtuzumab Then Chemo Offers No Benefit in Elderly AML Patients
November 13th 2013The sequential combination of gemtuzumab ozogamicin and standard chemotherapy offered no benefit in older patients with AML, and led to significant toxicities in those aged at least 70 years, according to results of a new study.
Chemo Plus Reduced-Dose RT Effective for Primary CNS Lymphoma
October 15th 2013Patients with primary central nervous system lymphoma had high response rates and good long-term disease control with a chemotherapy regimen followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in a new phase II trial.
The Place of Transplantation in Mantle Cell Lymphoma
October 15th 2013The role of transplant in MCL is in clinical evolution. Up-front high-dose therapy and autologous stem cell transplant remains an attractive option for those with chemosensitive disease regardless of the induction regimen chosen, whereas this approach in the relapsed or refractory setting has not yielded long-term disease-free intervals.
Novel Therapies in Mantle Cell Lymphoma: A Pathway to Chemotherapy-Free Strategies
October 15th 2013This review will cover innovative therapeutic approaches in relapsed or refractory MCL, many of which have the potential to alter treatment paradigms toward the development of strategies that do not involve conventional chemotherapy agents.
Panobinostat Recaptured Response in Bortezomib-Refractory Myeloma Patients
September 30th 2013The addition of the oral pan-deacetylase inhibitor panobinostat to bortezomib helped to elicit responses in about one-third of heavily pre-treated patients with multiple myeloma who were refractory of bortezomib, according to the phase II results of the PANORAMA 2 study.
Inherited Mutation Linked to Development of Pediatric ALL
September 21st 2013A mutation of the PAX5 gene has been found to play an important role in inherited cases of B-cell precursor acute lymphoblastic leukemia (B-ALL). The mutation was isolated in two unrelated families with high propensity for B-ALL.
Pomalidomide With Low-Dose Dexamethasone New Treatment Option for Multiple Myeloma
September 17th 2013Pomalidomide, an immunomodulatory drug, combined with low-dose dexamethasone improved progression-free survival in patients with refractory or relapsed and refractory multiple myeloma compared with standard of care high-dose dexamethasone, according to a new study.
Trial Suggests Imatinib Discontinuation Safe, Some Responses Persist
September 15th 2013Evidence continues to mount that discontinuing imatinib treatment for chronic myeloid leukemia (CML) in the chronic phase is safe. A new phase II Dutch and Belgian study showed only about two-thirds of patients relapsed after discontinuing treatment with imatinib and cytarabine, and all patients remained sensitive to imatinib after relapse.
Peripheral T-Cell Lymphoma: What’s the Role for Transplant?
September 15th 2013The number of recently approved agents and those under investigation is promising. However, there are currently no recommendations regarding the optimal timing for use of these agents, a reflection of the lack of data in this area and the need for prospective studies.
Peripheral T-Cell Lymphoma: Time for a T-Cell–Centric Standard of Care
September 15th 2013This is an exciting time in the treatment of PTCL, but with this opportunity comes responsibility. The challenge of how to optimize a plethora of promising new therapies for a small number of patients will drive therapeutic decision making for the foreseeable future.
Non-Secretory Myeloma: Clinical and Biologic Implications
September 15th 2013Myelomas that “lack” a monoclonal protein can be divided further into those that produce some protein and yet do not secrete it or whose serum concentration is so low that it cannot be measured, and those that truly produce no monoclonal protein at all.